Researchers launched a unique collaboration on Wednesday aimed at getting cancer drugs to the market more quickly in which three companies will cooperate with the U.S. government and non-profit groups to test five experimental breast cancer drugs.
The five-year, $26 million study called Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis, or I-SPY2, will aim to use DNA to match the best drug to each patient and to more quickly toss out approaches that do not work or are too toxic.
"They'll get the latest and greatest in terms of targeted drugs," Dr. Anna Barker, deputy director of the National Cancer Institute, said in an interview.
"I think it's the future. Government couldn't have done it on their own and these companies couldn't have done it on their own."
Unusually, the companies agreed to share information on using genes to predict how well a patient will respond as part of the Biomarkers Consortium, which includes the U.S. Food and Drug Administration and the National Institutes of Health.
"I-SPY 2 will provide a path to personalized medicine," said Dr. Laura Esserman, a breast cancer surgeon at the University of California San Francisco who will help lead the clinical trials. "We intend that every drug will graduate with a companion marker."
The trial will match patients to one of five experimental drugs:
-- ABT-888 or veliparib, being developed by Abbott Laboratories. The pill is a PARP inhibitor, which blocks a cell repair enzyme used by cancer cells.
-- AMG 655 or conatumumab, a targeted drug being developed by Amgen. It boosts a protein called APO/TRAIL that causes cancer cells to self-destruct.
-- Amgen's AMG 386, an angiogenesis inhibitor that stops tumors from growing blood vessels to nourish themselves.
-- CP-751,871 or figitumumab, being developed by Pfizer Inc to target the insulin growth factor receptor or IGFR.
-- Pfizer's HKI-272 or neratinib, another targeted therapy called a Pan ErbB inhibitor that targets several related receptors used by cancer cells.
The group is negotiating with other companies to add their experimental drugs to the mix.
"It'll speed up the whole process," Barker said.
The drug company lobby group PhRMA estimates it can take as long as 15 years and cost more than $1.3 billion dollars to take a new drug from laboratory to pharmacy.
Patients at 20 cancer centers will be tested right after they get tiny samples of tissue taken in biopsies. Before they ever get surgery, they will be treated with one of the drugs to see if this helps prevent tumor spread.
Up to 12 different cancer drugs will be tested. Unusually, the group has FDA approval to drop and add drugs throughout the course of the trial without having to stop it to write a whole new protocol.
A trilateral pledge will see a jump from the current collective clean power levels of about 37% to 50% by 2025
Around 6.5 million deaths globally are attributed each year to poor air quality inside and outside, making it the world's fourth-largest threat to human health, behind high blood pressure, dietary risks and smoking
New World Drug Report research identifies heroin as deadliest drug
Zika has caused alarm throughout the Americas since cases of the birth defect microcephaly were reported in Brazil, the country hardest hit by the outbreak
Philadelphia has become the first big city in the US to place a tax on soda to tackle the obesity crisis
Average global temperatures startlingly higher than normal between March-May
Government study provides strongest evidence of cell phone health effects
The reason for the high-level threat in the area is the presence there of Aedes aegypti mosquitoes, which carry the Zika virus that health authorities say causes birth defects in newborns
Three-day African Utility Week conference begins in South African city of Cape Town
More than two thousand activists came together to close an opencast coal mine in Germany.
New federal rules unveiled on Thursday will tackle the release of the greenhouse gas methane from oil wells and equipment as part of an effort to fight climate change.
At least five reef islands in the remote Solomon Islands have been lost completely to sea level rise and coastal erosion
Heads of UN, Work Bank lay out vision to deal with climate change
Turkish environment minister signs historic agreement in New York against taking action against climate change
Human defense mechanisms could be disrupted by the presence of a class of organic pollutants in fish and other food, according to new research.